Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
Open Access
- 31 May 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 17 (6), 647-649
- https://doi.org/10.1038/s41423-020-0426-7
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Monoclonal Antibodies for Emerging Infectious Diseases — Borrowing from HistoryThe New England Journal of Medicine, 2018
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigenProceedings of the National Academy of Sciences of the United States of America, 2017
- Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor bindingCell Research, 2016
- Structure, Function, and Evolution of Coronavirus Spike ProteinsAnnual Review of Virology, 2016
- Pre-fusion structure of a human coronavirus spike proteinNature, 2016
- Monoclonal antibody-based therapies for microbial diseasesVaccine, 2009
- Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigenNature Protocols, 2008
- Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with ReceptorScience, 2005